Have you had a chance to explore our recent whitepapers? Would you like to revisit the ones that caught your attention? Over the last four weeks, we published four whitepapers looking at a different aspect of how #DecentralizedManufacturing of cell and gene therapies can be achieved and used to increase accessibility for rural and global communities. You can read the entire series here: www.realm.bio/insights A BIG thank you to everyone who collaborated with us and helped to create this series! Domhnall Mc Gowan, Erika Francoeur, Craig Hasilo, Jenny Ligon, Stephen Stewart, and Enayat Mohammad, PMP
REALM Bio’s Post
More Relevant Posts
-
✔️ Looks like it was a great week in Liverpool from the feedback - Lots of change since I last attended the BioIndustry Association (BIA) BioprocessUK at the Manchester Midland, just before I moved to India. ⏳ The big subjects then were protein therapeutic processing and the importance of yield, stability, and aggregation. The focus has shifted since then to Gene & Cell Therapies, as you might expect - how to process and manufacture these innovative medicines more efficiently to maximise patient-benefit. 🧬 Whether it be mAbs or Gene Therapies, or any of the other cutting-edge modalities being developed to improve health, Malvern Panalytical Pharmaceuticals has the biophysical tech and knowledge to de-risk and speed up your development processes. For more, please see here: https://lnkd.in/gj57ZxMi #CGT #BioprocessUK #mAb #Biologics
This week at the BioIndustry Association (BIA)'s bioProcessUK 2024 event, Stephen Ward, Chief Technology Officer at the CGT Catapult, joined an panel discussion on #sustainable manufacturing. The panel provided expert insights into the future of cell and gene therapy and the need for manufacturing to align with commercial goals. Learn more about upcoming events we are involved in: https://ow.ly/6KH950Ub5Sf #bioProcessUK #BIA #CellandGene
-
-
Today at #ASGCT2024, Peter Cameron is presenting on our AI-powered approach to custom-building de novo gene editors. If #OpenCRISPR piqued your interest - or if you have another ambitious protein design campaign in mind - come find me or Anna Chase! 🎤 Language Models Generate Novel Genome Editors from scratch 📅 2 pm EST in Ballroom 1 #AI #GenerativeAI #ProteinDesign #CRISPR
At this week’s American Society of Gene & Cell Therapy’s 27th Annual Meeting, Peter Cameron will be giving an oral presentation highlighting the potential of our AI-powered approach for custom-building gene editors. Details below 👇 #ASGCT2024 #AI #GenerativeAI #ProteinDesign #CRISPR
-
-
🧦 What's the connection between socks & #cell & #gene therapies? At Vernal, they're both game changers! Our #mRNA platform is revolutionizing the path to commercialization & our socks are the hottest swag at #ASGCT2024. Swing by Booth #337, grab a pair & let's chat about how we're making cell & gene therapies smoother than a fresh pair of socks. 📸 Share your photos in the comments!
-
-
The next chapter of our #CRISPRlingo series offers a lesson in Latin. In vivo translates to “within the living,” and, in the context of gene editing, it refers to a targeted approach for editing genes within a patient’s body. Investigational in vivo #CRISPR therapies are typically delivered intravenously and designed to target specific cell types. Learn more: https://bit.ly/3LhSspB #InVivoTherapy To learn about ex vivo therapies, check out the next installment of our series. Scientia potentia est!
-
This week we're diving deep into the future of cell and gene therapy. Stop by our booth today or find us at the conference to learn more about how we’re driving innovation in market access and compliance!
Day 1 was full of energy at our booth, incredible keynote speakers, and getting a taste of beautiful Phoenix! The conversations on the future of cell & gene therapy have been insightful, and we’re just getting started. If you haven’t already, stop by our booth today—we’d love to connect and talk about how we’re transforming market access and compliance solutions. #CellAndGeneTherapy #MeetingOnTheMesa
-
So excited to share this Cencora white paper titled "Unraveling Payer Trends" (authored and led by Shaila Yoshida) as a consolidated resource of market research we've conducted over the past ~1 year. This includes >20 posters on value assessments, management of cell and gene therapies, opinions on PIE, use of AI in lit reviews, early access programs in the EU and more! Very cool to see findings from numerous research projects completed by my colleagues and I!! ▶ Follow this link to access the report: https://lnkd.in/ezeeDUPh
-
-
Director R&D at Cytiva | Strategic Leader in Cell Line Development Advancing Gene Therapy | Expert in Genomic Research and Analytical Assay Development
Did you know that impurities are a major CMC challenge with current AAV manufacturing processes? I was thrilled to give a presentation at ESACT today about our new ELEVECTA technologies improving AAV quality and addressing the future challenges in the gene therapy space. We can have a chat around this at our booth #72 or contact me if you want to know more!
-
-
Consider this 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 that will drive the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀. My presentation will focus on setting apart your therapy for payers through science. My panel will discuss strategies for cross-functional collaboration. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲 – https://ter.li/lhvjuu
-
-
Don't forget to sign up for the Biophysical Summit hosted by Applied Photophysics and KBI Biopharma! 🏔 This summit will highlight some of the latest analytical techniques for developing and characterizing protein and gene therapies. Come with your questions and learn how companies tackle the characterization of novel modalities! Register here: https://bit.ly/3TxZawo #BiophysicalSummit #KBI #AppliedPhotophysics
-
-
Check out the latest advancement in post-transplant care! Dr. John Friedewald, along with Dr. Ram Peddi and Dr. Michael Marvin, explored case studies revealing the benefits of gene expression tests. Learn how these tests detect subclinical rejection, guiding personalized treatment approaches. Dive into the article: https://loom.ly/ezIagGk
-
